Citigroup’s Turnstone Biologics TSBX Stock Holding History

Citigroup’s Portfolio TSBX Stock Details TSBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-61,413	Closed	-$30.4K	–	5969
2024 Q4	$30.4K	Buy	+61,413	New	+$30.3K	﹤0.01%	5202
2024 Q3	–	Sell	-24,825	Closed	-$65K	–	5803
2024 Q2	$65K	Buy	24,825 +21,886	+745%	+$62.6K	﹤0.01%	4441
2024 Q1	$7.7K	Buy	2,939 +1,922	+189%	+$5.5K	﹤0.01%	5258
2023 Q4	$2.59K	Sell	1,017 -6,507	-86%	-$17K	﹤0.01%	5400
2023 Q3	$29.6K	Buy	+7,524	New	+$67.1K	﹤0.01%	4284

Other funds holding TSBX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's TSBX Position: Q1 2025 in Review

Citigroup sold out of Turnstone Biologics (TSBX) in Q1 2025, closing a stake of 61,413 shares — an estimated $30.4K sold.

Citigroup first reported a position in TSBX in Q3 2023 and held it in 5 quarters. The position peaked at $65K in Q2 2024. 23 funds tracked by Wall St. Rank hold TSBX as of Q1 2025.

Citigroup reported no remaining Turnstone Biologics position as of Q1 2025 after selling out during the quarter.
Citigroup sold 61,413 Turnstone Biologics shares in Q1 2025, an estimated $30.4K.
Citigroup first reported a position in Turnstone Biologics in Q3 2023 and held it in 5 quarters.
Citigroup's Turnstone Biologics position peaked at $65K in Q2 2024.
23 funds tracked by Wall St. Rank held Turnstone Biologics as of Q1 2025.

Based on Citigroup's 13F filing for Q1 2025, filed 12 May 2025.